As Makati Medical Center celebrates its 50th Anniversary this year, the premiere hospital continues to drive advancement in medical care in the country by forging a partnership with one of the leading cancer centers in the United States.
MakatiMed has partnered with UC Davis Comprehensive Cancer Center (UCDCCC) in a bid to boost cancer care in the Philippines. The agreement with the University of California, Davis-affiliated medical center includes the development of an international Cancer Care Network, a cancer registry in MakatiMed, training programs for cancer care, a second opinion program, and on-site clinical rotation from various subspecialties in oncology.
Inpatient and outpatient procedures will be evaluated to enhance clinical workflows. The two hospitals will also share telemedicine programs and potentially collaborate in clinical trials, research studies, seminars, and multi-disciplinary teleconferences.
UCDCCC, which was designated as a comprehensive cancer center by the US National Cancer Institute, offers the most advanced methods for the diagnosis, prevention, and treatment of cancers and blood disorders.
“We want to introduce a collaborative approach in cancer care to offer the ideal treatments to our patients,” says Maria Corazon C. Consunji, MD, MakatiMed President and CEO. “This partnership will help MakatiMed achieve the best patient outcomes by embracing the advancements in oncology.”
Dr. Consunji inked the contract with Primo N. Lara, Jr., MD, UCDCCC Director. Also present in the contract signing were UCDCCC’s Gina Dayton, Chief Administrative Officer and Associate Director for Administration, and Kristin Jones, Director for Oncology Services.
For more information, please contact MakatiMed On-Call at +632.8888 999, email [email protected], or visit www.makatimed.net.ph.
TAGS: blood disorders, cancer, cancer care, Cancer Care Network, cancer disorders, diagnosis, diagnosis of blood disorders, Gina Dayton, Jr, Kristin Jones, Makati Med, Makati Medical Center, Maria Corazon C. Consunji, oncology, prevention, prevention of blood disorders, Primo N. Lara, treatment, UC Davis Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center (UCDCCC), UCDCCC, University of California
A simple inexpensive eye test could lead to quicker diagnosis of autism.
The findings of a study conducted by a team of researchers at Washington State University revealed that a penlight reflex test could one day diagnose autism.
Dr Georgina Lynch, an assistant clinical professor of speech-language pathology, and her team tested 24 participants, aged 10 to 17. Half of the group had been diagnosed with high-functioning autism, while the other half did not have the condition.
In the four trials, the researchers measured the pupil reflexes in response to light in each eye for four seconds each trial.
In 70% percent of the cases, the researchers observed that the pupils of children diagnosed with autism took markedly longer to constrict.
“Our results suggest that an inexpensive, noninvasive pupil penlight reflex test could be a physiological measurement of autism,” Dr Lynch explained.
The research team intends to follow up the study by conducting the test on a larger group of children which will include participants younger than 10.
According to Dr Lynch, people with autism exhibit difficulty in making eye contact and are often sensitive to bright lights. Children with autism find it challenging to maintain an eye gaze because of the deficient functioning of the two cranial nerves. Dr Lynch stressed that the fundamental physical behaviors are needed to develop language as well as socialization.
“If a simple technology can be used by paediatricians to spot a likely sign of autism during routine exams, then we can get these kids a quicker diagnosis and quicker treatment. The sooner we can intervene with proven techniques, the better their chances in the world,” Dr Lynch concluded